Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

7.270 -0.090 (-1.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,704,019
Open 7.400
Bid (Size) 7.100 (2)
Ask (Size) 7.260 (7)
Prev. Close 7.360
Today's Range 7.045 - 7.400
52wk Range 2.090 - 14.84
Shares Outstanding 70,895,286
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From Rosen Law Firm
Via Business Wire

Performance

YTD
-30.89%
-30.89%
1 Month
-15.56%
-15.56%
3 Month
-22.58%
-22.58%
6 Month
+172.28%
+172.28%
1 Year
+47.76%
+47.76%

More News

Read More
ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Peering Into Altimmune's Recent Short Interest
Via Benzinga
How Is The Market Feeling About Altimmune?
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
Jim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment'
Via Benzinga
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Deutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
Via InvestorPlace
Altimmune's Earnings Outlook
Via Benzinga
(ALT) - Analyzing Altimmune's Short Interest
Via Benzinga
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Via The Motley Fool
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Via InvestorPlace
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Via The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Via MarketBeat
Exposures Product Safety
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
Via Investor's Business Daily
7 Stocks That Will Drive the Weight Loss Drugs Market
Via MarketBeat
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 27, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.